Zobrazeno 1 - 10
of 335
pro vyhledávání: '"Yan Ou"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundImmune checkpoint inhibitors (ICIs) are an emerging tumor treatment pathway after traditional surgery, chemoradiotherapy, and targeted therapy. They have proven to be effective in a variety of cancers, but may not respond to non-target popu
Externí odkaz:
https://doaj.org/article/f667322870e241dda57b2ad04d182360
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
Background and ObjectiveEnhancing therapy choices for varying stages of esophageal cancer and improving patient survival depend on timely and precise diagnosis. Blood metabolites may play a role in either causing or preventing esophageal cancer, but
Externí odkaz:
https://doaj.org/article/971140e07646457f81f59dc2caaed657
Autor:
Qiyunna He, Yan Ou, Huili Zhu, Zhiqian Chen, Dailan Yang, Qian Cheng, Xia Yin, Lina Xiao, Lin Cai, Yan Ye, Xin Xu, Juan Liao
Publikováno v:
JGH Open, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Background and Aim To evaluate the efficacy and safety of minocycline, vonoprazan, amoxicillin, and bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment. Methods From August 2022 to May 2023, clinical data were collected f
Externí odkaz:
https://doaj.org/article/d7abf6fcbf5a4f19bf12cd82a3d0e311
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Pancreatic cancer is one of the deadliest malignant tumors, which is a serious threat to human health and life, and it is expected that pancreatic cancer may be the second leading cause of cancer death in developed countries by 2030. Claudin18.2 is a
Externí odkaz:
https://doaj.org/article/4e138550f2e949f8bec191d8251c4ead
Publikováno v:
Translational Oncology, Vol 41, Iss , Pp 101893- (2024)
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. The number of cases increased by 2.26 million in 2020, making it the most commonly diagnosed cancer type in the world. TNBCs lack hormone receptor (HR) and human
Externí odkaz:
https://doaj.org/article/0305601a4a31491498746d3ceb0c6951
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Various new treatments are emerging constantly in anti-tumor therapies, including chemotherapy, immunotherapy, and targeted therapy. However, the efficacy is still not satisfactory. Astragalus polysaccharide is an important bioactive compone
Externí odkaz:
https://doaj.org/article/615f4c5d937449528dcb4065d5ab239c
Autor:
Stefan Mrdenovic, Yanping Wang, Lijuan Yin, Gina Chia-Yi Chu, Yan Ou, Michael S. Lewis, Marija Heffer, Edwin M. Posadas, Haiyen E. Zhau, Leland W. K. Chung, Mouad Edderkaoui, Stephen J. Pandol, Ruoxiang Wang, Yi Zhang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is notorious for its resistance to both chemotherapy and small-molecule inhibitor targeted therapies. Subcellular targeted cancer therapy may thw
Externí odkaz:
https://doaj.org/article/64d9337c28904376b1c490cb73e2bfef
Autor:
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong, Dan Yi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/a2700b8c46b647af842674877fc3f5dd
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 17, Iss 1, Pp 1-8 (2022)
Abstract Introduction The efficacy of azithromycin to prevent exacerbation for non-cystic fibrosis bronchiectasis remains controversial. We conduct this meta-analysis to explore the influence of azithromycin versus placebo for the treatment of non-cy
Externí odkaz:
https://doaj.org/article/9ee272cbb13349018cde140a79d19f20
Autor:
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong, Dan Yi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applicatio
Externí odkaz:
https://doaj.org/article/4092bc83fc064b0d91a7103a330f963e